U.S. markets closed

Blog Coverage MyoKardia Announced Receipt of Payment from Sanofi

LONDON, UK / ACCESSWIRE / December 5, 2016 / Active Wall St. blog coverage looks at the headline from MyoKardia, Inc. (NASDAQ: MYOK) as the company announced receipt of milestone payment from Sanofi (NYSE: SNY). MyoKardia received a $25 million milestone payment in accordance with the research agreement between the Company and Sanofi (SNY) established in August 2014 for the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MYK-491 in dilated cardiomyopathy (DCM). Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

Today, AWS is promoting its blog coverage on MYOK and SNY. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=MYOK

http://www.activewallst.com/registration-3/?symbol=SNY

"We are pleased to be moving into the clinic in the first half of 2017 with the second product candidate from MyoKardia's precision medicine platform," said Robert McDowell, Ph.D., senior vice president, drug discovery at MyoKardia, "Both the Company's initial product candidate for HCM, now in Phase 2, and our investigational therapy for DCM may correct the inappropriate power output caused by sarcomere mutations that is an underlying driver of disease progression."

Top-line results from the planned Phase 1 single ascending dose study of MYK-491 in healthy volunteers are expected in Q3 2017. MYK-491 is designed to increase the overall force of the heart's contraction in DCM patients by increasing cardiac contractility. MyoKardia intends to initiate a Phase 1 study of MYK-491 in healthy volunteers in the first half of 2017.

The Agreement with Sanofi

Sanofi and MyoKardia, which was then privately-held, announced a worldwide collaboration to discover and develop targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration provides up to $200 million in equity investments, milestone payments, and research and development services through 2018, of which $45 million were already paid in an upfront licensing fee and an initial equity investment. Furthermore, the agreement stated that Sanofi and MyoKardia will equally share development costs on the HCM programs following initial demonstration of efficacy in patients, with Sanofi fully covering the development costs of the DCM program.

Announcement for Chief Medical Officer

On December 01, 2016, MyoKardia announced that Marc Semigran, M.D., has joined the Company as Chief Medical Officer. In his new position, Dr. Semigran will oversee clinical development and lead MyoKardia's clinical trial strategy. Most recently, Dr. Semigran led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran has been a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School.

Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General. Dr. Semigran has published more than 140 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. He is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic, and Bayer.

Stock Performance

At the closing bell, on Friday, December 02, 2016, MyoKardia's stock climbed 3.45%, ending the trading session at $16.50. A total volume of 93.97 thousand shares were traded at the end of the day. In the last month and previous six months, shares of the company have rallied 16.61% and 33.50%, respectively. Moreover, the stock gained 12.55% since the start of the year.

Sanofi's share price finished Friday's trading session at $40.02, slightly up by 0.76%. A total volume of 1.47 million shares exchanged hands. The stock has advanced 0.68% and 2.14% in the last month and past three months, respectively. The stock is trading at a PE ratio of 23.28 and has a dividend yield of 4.15%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street